71 results about "Hematological Tumor" patented technology

The invention provides a hematologic tumor cord blood transplantation treatment prognosis risk assessment method and system based on multi-modal data fusion, a medium and electronic equipment, and relates to the technical field of medical artificial intelligence and clinical decision support systems. The method comprises the following steps: acquiring multi-modal data including unit characteristic data of cord blood of a patient, biomarker data and the like; screening out a simplified feature set from the preprocessed multi-modal data; fusing the simplified features based on three complementary strategies of feature level direct cascade, knowledge graph semantic association and multi-model decision integration; and a prediction model is constructed, and a standardized risk assessment report is generated based on the optimized hierarchical risk levels and is used for assisting clinical decision support. According to the method, accurate layering of the prognosis risk of the hematologic tumor umbilical cord blood transplantation patient is achieved, high-accuracy risk prediction is provided, good interpretability and personalized decision support capacity are achieved, and a scientific basis is provided for clinical practice.

Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, and egg secreted proteins. (hereinafter referred to as “Schistosoma eggs and secretions and excretions thereof” for short). A Schistosoma infection can significantly inhibit metastatic tumors of organs such as lungs, and an anti-tumor effect is mediated by the “Schistosoma eggs and secretions and excretions thereof”, which have the effect of inhibiting various host tumors, comprising lung cancer, liver cancer, melanoma, and hematological tumors. Two egg secreted proteins having an anti-tumor effect are further identified. The “Schistosoma eggs and secretions and excretions thereof” exert an anti-tumor effect by activating natural immunity such as alveolar macrophages. The “Schistosoma eggs and secretions and excretions thereof” have a potential application value in prevention and treatment of tumors in humans.

The present disclosure provides a group of aromatic (e.g., pyridinyl, pyrimidinyl, pyrazinyl, or phenyl) diamidine analogs and pharmaceutically acceptable salts that are useful for treating a proliferative disease. The proliferative disease may include solid cancer or blood cancer. Compositions, methods of synthesizing the same and methods for treating various cancer using the analogs are disclosed herein. The present disclosure also provides pharmaceutical formulations comprising at least one of the compounds with a pharmaceutically acceptable carrier, diluent or excipient therefor.

The invention relates to the technical field of image recognition, and particularly discloses an auxiliary blood tumor pathological diagnosis system and method based on artificial intelligence, and the system extracts a pathological image group of a patient through a pathological diagnosis auxiliary platform, analyzes the data of each pathological image, and judges the effective feature value of each pathological image; the effective feature values of the pathological images are compared with a predefined effective feature threshold value to obtain a comparison result, and the pathological diagnosis auxiliary platform judges whether the effective features of the pathological images are enhanced or not based on the comparison result; and extracting cell characteristic data in each pathological image according to each pathological image, judging the characteristic complexity of each pathological image, and performing difference analysis on the pathological image group to complete auxiliary blood tumor pathological diagnosis.

The present invention relates to therapeutic treatment of cancer, particularly solid and hematological tumors, with combination therapy using PM14 and a topoisomerase I inhibitor.

The present disclosure provides methods and systems for genomic data representation and estimation of various biomarkers of interest in personalized medicine and particularly in cancer genomics such as molecular residual disease (MRD), tumor fraction (TF), blood tumor mutational burden (bTMB) and clonal hematopoiesis of indeterminate potential (ChIP).

The invention provides an extraction method of high-performance gamma delta T immune cells and application of the high-performance gamma delta T immune cells in tumors. The method comprises the following steps: firstly, separating mononuclear cells from peripheral blood, carrying out activation induction by using a serum-free culture medium containing zoledronic acid, IL-15 and OKT3, and supplementing a culture medium containing IL-2 according to a specific proportion for multiplication culture from the third day of culture. Through the optimization process, the expression rate of TCR-gamma delta < + > is as high as 96.84%, and gamma delta T cells with high activity are obtained. An in-vivo tumor inhibition experiment shows that the cell has a remarkable growth inhibition effect on liver cancer nude mouse transplanted tumor, the effect is equivalent to that of a positive control drug, and obvious toxic and side effects are not observed. The method is stable in process and clear in component, and a reliable technical basis is provided for clinical transformation of gamma delta T cells in immunotherapy of solid tumors and hematologic tumors.

This invention belongs to the fields of medicinal chemistry and pharmaceutical technology, and relates to 1,4-benzodiazepines and their use in the preparation of antitumor drugs, specifically the use of 1,4-benzodiazepines in the preparation of annexin A3 (ANXA3) degrading agents and in the preparation of drugs for treating cancer. In particular, it discloses the use of 1,4-benzodiazepines, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or compositions of drugs with these as active ingredients, in the preparation of drugs for the prevention and treatment of tumors. These compounds can bind to the ANXA3 protein, induce ANXA3 protein degradation, inhibit the proliferation, cloning, migration, and invasion of tumor cells, and exert antitumor therapeutic effects in vivo. They can be used to treat solid tumors and hematological malignancies, including breast cancer, cervical cancer, ovarian cancer, colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, esophageal cancer, liver cancer, leukemia, and melanoma.

The present application relates to the technical field of medical devices, in particular to a wound debridement device for blood tumor patients, comprising a handle vertically arranged, an injection part, an adsorption part and a mounting part for clamping medical cotton, the lower end of the handle is provided with a placing cavity, the mounting part is arranged in the placing cavity, the injection part comprises a first cylindrical cavity, a first button, a vertical slide and a first flow channel arranged in the handle, the mounting part comprises a fixing block arranged in the placing cavity and detachably connected with the handle, when the medical cotton is clamped on the handle by the fixing block, part of the medical cotton extends out of the lower end of the handle through the center hole of the fixing block, and the adsorption part comprises a second cylindrical cavity, a second button and an adsorption channel arranged vertically. The present application is simple and fast in operation when debriding the wound of the patient, greatly shortens the debridement time and reduces the labor intensity of medical staff, simultaneously reduces the time of exposing the wound of the patient to the outside, reduces the risk of wound infection and improves the wound healing speed.

Disclosed are compositions and methods for targeted treatment of cancer, such as hematologic cancer. In particular, chimeric antigen receptor (CAR) T cells are disclosed that can be used with adoptive cell transfer to target and kill cancer cells with reduced antigen escape. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with hematologic cancer that involves adoptive transfer of the disclosed CAR T cells.

The application provides a novel DNA methylation marker TAGMe-5 for tumor identification and use thereof. The tumor marker TAGMe-5 of the application shows significant DNA methylation difference between cancer adjacent tissue and cancer tissue, and the difference has significant statistical significance, and the difference is shown in numerous tumors such as solid tumors and non-solid tumors. The solid tumors include lung cancer, liver cancer, prostate cancer, cervical cancer, endometrial cancer, urothelial carcinoma, biliary tract tumor, etc. The non-solid tumors include hematological tumors, lymphoma, etc. Therefore, the tumor marker of the application can be used for clinical screening of pan-cancer, molecular diagnosis, prognosis and efficacy evaluation.

Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.

The application provides a CAR-T cell therapy toxicity management optimization method and system, relates to the technical field of artificial intelligence, and comprises the following steps: acquiring clinical data of a blood tumor patient receiving a CAR-T cell therapy; performing missing value interpolation and standardization processing on baseline characteristic information and process monitoring data to obtain a standardized data set; obtaining a calibrated virtual patient physiological model according to a preset tumor cell kinetics model, an immune cell kinetics model and a toxicity reaction model; taking the calibrated virtual patient physiological model as an interactive environment to obtain a correlation database; constructing a deep Q network intelligent agent with a maximum reward function as a target to obtain an optimized deep Q network intelligent agent; and inputting the process monitoring data into the optimized deep Q network intelligent agent to obtain a target strategy, so that the individualized CAR-T treatment strategy balancing the therapeutic effect and toxicity can be automatically output by inputting the real-time monitoring data of the patient.

The invention belongs to the technical field of gene sequencing, and particularly relates to a library building kit and probe for detecting blood tumor related fusion genes. According to the library building kit, only a trace amount of total RNA is needed to be used for cDNA synthesis, the initial quantity of a template can be as low as 10 ng, so that a cDNA library is built, then the library is subjected to hybrid capture and enrichment by using an autonomously designed probe hematologic tumor fusion gene Panel (RA Panel), the time consumption is short, the efficiency is high, and simultaneous building and on-machine sequencing of 384 libraries can be realized. According to the rapid hybridization system of the library building kit, the shortest hybridization time can reach 30 min, the size of a finally obtained library fragment is about 200-400 bp, and the rapid hybridization system can be compatible with various Illumina sequencing platforms for sequencing. According to the invention, through a simple and easy-to-use solution of NGS sequencing while synthesis, rapid and accurate typing of fusion genes which may affect blood tumor diagnosis is realized.

The invention provides an immortalized T cell line SZ906 derived from peripheral blood of a hematoma patient as well as a preparation method and application of the immortalized T cell line SZ906. The immortalized T cell line SZ906 derived from the peripheral blood of the hematoma patient is preserved in Guangdong Microbial Culture Collection Center on December 25, 2025, and the preservation number is GDMCC No: 67533. The immortalized T cell line SZ906 derived from the peripheral blood of the hematoma patient, provided by the invention, can still keep good multiplication capacity and high survival rate in a long-time (more than one year) culture process, has strong cytotoxicity to tumor cells, and can kill the tumor cells and remove cells infected by pathogens.

To provide a process for preparing MDM2 inhibitors useful for treating solid tumors such as breast, colon, lung, and prostate tumors, as well as liquid tumors such as lymphomas and leukemias.SOLUTION: Provided are commercial processes for preparing 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid and intermediates thereof.SELECTED DRAWING: Figure 1

In combination with conventional therapies (e.g., targeted therapy, chemotherapy, and angiogenesis inhibitors etc.), immunotherapies targeting checkpoint molecules have shown promise in the treatment of solid or liquid tumors. However, apoptotic regulatory T cells (Treg) induced by such therapies often become more suppressive in the tumor microenvironment (TME), through increased generation of adenosine tightly controlled by ectonucleotidases, viz. CD39 and CD73. CD39 / ENTPD1, a novel checkpoint molecule, is highly expressed and activated on the tumor vasculature and infiltrating immune cells, promoting tumor growth. Deletion or blockade of CD39 enhances anti-tumor activity by augmenting anti-tumor immune responses and inhibiting tumor angiogenesis. The present invention is based at least in part on the development of anti-CD39 antibodies which mediate CD39 downregulation on immune cells, such as T-cells with markers of T-cell exhaustion, and the demonstrated utility of these antibodies in blocking tumor growth with minimal side effects in pre-clinical models.

The present invention relates to therapeutic treatment of cancer, particularly solid and hematological tumors, with combination therapy using Compound IA and a topoisomerase I inhibitor.

The invention relates to an application of 7-phenylcarbamoyl heptanoic acid in preparation of antitumor drugs, in particular to a new application of 7-phenylcarbamoyl heptanoic acid in preparation of antitumor drugs, which develops the medicinal value of 7-phenylcarbamoyl heptanoic acid and has high antitumor activity on solid tumors or hematologic tumors. In-vivo experiments show that under an effective dose, the 7-phenylcarbamoyl heptanoic acid does not cause obvious weight loss, weight change of main organs or histopathologic injury of experimental animals, so that the 7-phenylcarbamoyl heptanoic acid has a relatively good treatment window and good safety.

The invention discloses application of Venetoclax in preparation of a medicine for preventing and / or treating nasopharyngeal carcinoma, and particularly, the Venetoclax inhibits expression of ACSBG1 protein and can be used for treating the nasopharyngeal carcinoma. The anti-tumor mechanism of Venetoclax relates to regulation and control of fatty acid metabolism or mitochondrial functions, and can reverse the drug resistance of tumor cells to cis-platinum. According to the invention, Venetoclax is expanded from a BCL-2 inhibitor in hematologic tumor treatment to an ACSBG1 inhibitor for solid tumor nasopharyngeal carcinoma, belongs to a brand-new and expected'new use of old medicine ', and shows remarkable innovation potential.

The invention belongs to the technical field of gene sequencing, and particularly relates to a library building kit and a probe for detecting hematologic tumor chemotherapy related gene polymorphism by using a hybrid capture method. According to the present invention, the genotype of the hematologic tumor chemotherapy related gene, the drug treatment effect, the toxicity and the metabolic capability related information can be rapidly obtained through the one-time detection; meanwhile, the library building kit is simple and convenient to operate and short in consumed time, and automatic detection is extremely easy to realize. The detection result completed by using the library building kit is accurate, and the library building kit has important reference significance for treatment and prognosis of hematologic tumor patients needing chemotherapy.

The invention provides a multiple myeloma detection system based on single cell in-situ sequencing. The CosMxSMI technology is applied to hematologic tumors for the first time, limitation of solid tissues is broken through, and synchronous analysis of cell types, RNA and protein in-situ expression in a bone marrow microenvironment is achieved. A single-cell suspension sample smaller than 1 mL is used, common protein targets are subjected to flow analysis based on RNA FISH and MM of an MM-related customized panel, and information such as bone marrow or peripheral blood single-cell-level cell types, proportions, RNA and protein expression profiles and the like can be obtained in situ on a slide microarray at the same time. Traditional FISH, flow cytometry and GEP step-by-step detection are replaced, manpower of the pathology department and a blood cell chamber is saved, the sample collection amount, loss and operation errors are reduced, and the clinical report time is shortened by 80%.

This application provides a method and related equipment for constructing a clonal evolution atlas of hematologic malignancies. The method includes acquiring batch sequencing data and extracting a set of complementarity-determining region (CDR) sequences from the batch sequencing data; filtering the CDR sequence set for pseudoclones to obtain a first sequence set; clustering the CDR sequences in the first sequence set based on edit distance to obtain multiple clonal clusters; performing evolutionary co-validation on clonal pairs in the clonal clusters at multiple time points to obtain an evolutionary trend score; filtering the clonal clusters at multiple time points based on the evolutionary trend score to obtain a clonal evolution time series; and constructing a clonal evolution atlas based on the clonal evolution time series. This method can improve the accuracy of the constructed clonal evolution.

The present invention is directed to humanized CD37-CAR comprising humanized CD37 scFv of the present invention. The present invention is also directed to a bispecific CD19-humanized CD37 CAR, comprising: (i) CD19 VL, (ii) Humanized CD37 ScFv, (iii) CD19 VH, (iv) a transmembrane domain, (v) at least one co-stimulatory domains, and (vi) an activating domain. The CARs of the present invention are useful in the field of adoptive immunity gene therapy for hematological cancers.

The application belongs to the field of medicine, and relates to application of a pyrrolopyridine-containing compound in treatment of tumors, in particular to application of a compound of formula (I-1) or a pharmaceutically acceptable salt thereof in treatment of hematological tumors, wherein the hematological tumors are selected from relapsed and / or refractory hematological tumors

The application provides a gene set and kit for evaluating the curative effect after allogeneic hematopoietic stem cell transplantation of hematopathy, and belongs to the field of gene detection. The application develops a new post-transplantation curative effect evaluation panel detection design method. The panel comprises: 1. single nucleotide polymorphism (SNP) sites characteristic of individual genetic characteristics, which can be used for graft implantation evaluation; 2. high-frequency mutation sites of blood tumor hotspot genes, which can be used for MRD detection and disease state evaluation; and 3. HLA gene characteristic SNP sites on the short arm of human chromosome 6, which can be used for HLA gene typing, combined with the state of graft implantation, to analyze the occurrence of HLA-loss. The technical scheme of the application can solve the above-mentioned multiple contents of post-transplantation curative effect evaluation at one time, is more accurate and sensitive than the previous detection method, and can greatly reduce the detection cost and shorten the clinical report time.

The application discloses a pyridazinone derivative with PARP7 / HDAC dual-target inhibition activity, and a preparation method and application thereof. The application provides a pyridazinone derivative with PARP7 / HDAC dual-target inhibition activity shown in a structure of formula (I), a pharmaceutical composition containing the derivative of formula (I), and a hydrate, and isotopic derivatives, chiral isomers, conformers, different salts, prodrugs and preparations of the compounds. The application also provides a preparation method of the pyridazinone derivative with PARP7 / HDAC dual-target inhibition activity, and application of the compounds in treatment of solid tumors and hematological tumors.

The invention discloses an artemisinin compound containing a 10-bit ether side chain or a pharmaceutical salt thereof, the structural general formula is one of the following structures: the artemisinin compound containing the 10-bit ether side chain provided by the invention has a relatively obvious proliferation inhibition effect on liver cancer HepG2, lung cancer A549, intestinal cancer HCT116, hematologic tumors MV-4-11 and HL-60; the anti-tumor activity of part of the compounds is higher than that of commercially available drugs SAHA and belinostat, and the compounds are expected to be developed into novel anti-tumor drugs. In addition, the performance of a plurality of compounds is superior to the in-vitro antimalarial activity of artemisinin, and the compounds are expected to be developed into novel antimalarial drugs.

The invention relates to a triploid and / or copy number neutral heterozygosity deletion detection method and device and application, and belongs to the technical field of biological information. The method comprises the following steps: 1) acquiring genome sequencing comparison data of a sample to be detected; 2) performing bin division processing on the genome sequencing comparison data, determining SNP (Single Nucleotide Polymorphism) feature information in each bin, and performing bin filtering based on the feature information; 3) constructing a reference baseline by using a normal sample; and 4) based on the steps 1)-3), performing triploid and / or copy number neutral heterozygosity deletion detection on the to-be-detected sample. According to the method, detection can be completed based on low-depth genome sequencing data, the detection cost is effectively reduced, and the detection accuracy and sensitivity are improved through bin division and SNP feature information filtering. A reference baseline constructed by a normal sample is used for constructing a dynamic threshold value, so that the reliability of a detection result is enhanced, and the method is suitable for various scenes such as prenatal diagnosis, genetic diseases and hematologic tumors.